Kymera Therapeutics has appointed Terence Rooney, MD, as its new Chief Medical Officer. Dr. Rooney, formerly Senior Vice President and immunology portfolio leader at Johnson & Johnson, will oversee global clinical development strategy for the company's oral small molecule degrader pipeline targeting multiple immuno-inflammatory diseases. He succeeds Jared Gollob, MD, who is retiring after eight years with Kymera and will remain as an advisor through the end of 2026. Dr. Rooney brings experience from leadership roles at Johnson & Johnson, Eli Lilly, and Roche, and has contributed to marketing applications for medicines including ICOTYDE, IMAAVY, OLUMIANT, STELARA, and TREMFYA.
Kymera Therapeutics IncAppointment of experienced CMO to lead clinical development of degrader pipeline.
Johnson & Johnson
Eli Lilly and Company
Roche Holding AG